Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes
- 4 November 2002
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 18 (6) , 484-490
Abstract
Background: Postprandial hyperlipemia and small, dense LDL particles are features of dyslipidemia in type 2 diabetes. The purpose of this study was (1) to determine whether the oral insulinotropic drugs, nateglinide and glibenclamide, can overcome the defect of insulin action to suppress the hepatic VLDL release after a meal and decrease the postprandial lipemia and (2) to evaluate the acute effect of postprandial hypertriglyceridemia on LDL particle size in subjects with type 2 diabetes.Methods: Forty‐three subjects with type 2 diabetes and mean baseline HbA1c 7.6% (95% CI 7.3 to 7.9) were treated with nateglinide 120 mg three times daily or glibenclamide 5 mg once or twice daily for 12 weeks in a double‐blind randomised trial. Insulin, glucose, and lipoprotein responses to a mixed fat‐rich meal were determined for 8 h postprandially at baseline and at 12 weeks on‐trial.Results: Nateglinide and glibenclamide significantly augmented the maximal response in serum insulin at 60 min postprandially compared with the response without the drug [additional increase 25.0 mU/l (95% CI 11.2–38.8) p = 0.001 and 12.5 mU/l (95% CI 4.6–20.3) p = 0.003, respectively] and reduced hyperglycemia. Neither drug affected fasting or postprandial lipid or lipoprotein levels. LDL size did not significantly change in the 8‐h postprandial period.Conclusions: Although nateglinide and glibenclamide increase postprandial insulin secretion and attenuate hyperglycemia, they do not alleviate postprandial lipemia in subjects with type 2 diabetes and good glycemic control. Although small LDL particle size is associated with chronic hypertriglyceridemia, LDL size does not change during acute postprandial hypertriglyceridemia. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart DiseaseCirculation, 2001
- Importance of Early Insulin SecretionDiabetes Care, 2001
- Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitusDiabetic Medicine, 2000
- Remnant Lipoprotein Levels in Fasting Serum Predict Coronary Events in Patients With Coronary Artery DiseaseCirculation, 1999
- Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart StudyDiabetes Care, 1998
- Postprandial Elevation of ApoB-48-Containing Triglyceride-Rich Particles and Retinyl Esters in Normolipemic Males Who SmokeArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Defective regulation of triglyceride metabolism by insulin in the liver in NIDDMDiabetologia, 1997
- Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)‐N‐(trans‐4‐isopropylcyclohexane‐carbonyl)‐d‐phenylalanine (A‐4166)British Journal of Pharmacology, 1997
- Diabetic Dyslipidemia: Basic Mechanisms Underlying the Common Hypertriglyceridemia and Low HDL Cholesterol LevelsDiabetes, 1996
- Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.Circulation, 1990